剖宫产术后口服头孢氨苄与甲硝唑对肥胖女性手术部位感染的影响:一项随机临床试验
该随机双盲临床试验在肥胖女性(孕前BMI≥30)剖宫产术后比较口服头孢氨苄500mg与甲硝唑500mg每8小时共48小时与安慰剂的SSI发生率,头孢氨苄-甲硝唑组SSI 6.4% vs 安慰剂组15.4%(RR 0.41,95%CI 0.22-0.77,P=0.01),两组均无严重不良事件。
要点
- 肥胖女性剖宫产术后口服头孢氨苄加甲硝唑48小时,SSI发生率6.4% vs 安慰剂组15.4%。
- 相对风险RR 0.41(95%CI 0.22-0.77),P=0.01,差异9.0%(95%CI 2.9%-15.0%)。
- 两组均未报告严重不良事件(包括过敏反应)。
核心结论
- 在接受标准术前头孢菌素预防的肥胖剖宫产女性中,术后48小时口服头孢氨苄和甲硝唑较安慰剂降低了分娩后30天内SSI发生率。
- 作者认为,对于肥胖女性剖宫产术后预防SSI,预防性口服头孢氨苄和甲硝唑可能是有理由的。
研究设计与样本
- 随机双盲临床试验,比较剖宫产术后48小时口服头孢氨苄和甲硝唑与安慰剂预防SSI,纳入孕前BMI≥30且已接受标准静脉术前头孢菌素预防的肥胖女性。
- 随机化按分娩前胎膜完整与胎膜破裂分层,研究于2010年10月至2015年12月在俄亥俄州辛辛那提大学医学中心进行,最终随访至2016年2月。
主要发现
- 共纳入403名随机参与者(平均年龄28岁,SD 6;平均BMI 39.7,SD 7.8),382名(94.6%)完成试验。
- 总体SSI发生率为10.9%(95%CI 7.9%-14.0%)。
- 头孢氨苄-甲硝唑组13名女性(6.4%)诊断SSI,安慰剂组31名女性(15.4%)诊断SSI,差异9.0%(95%CI 2.9%-15.0%),相对风险0.41(95%CI 0.22-0.77),P=0.01。
- 抗生素组或安慰剂组均未报告严重不良事件,包括过敏反应。
关键数值与推荐
- 干预方案:口服头孢氨苄500mg和甲硝唑500mg,每8小时一次,共48小时,剖宫产术后开始。
- 主要结局SSI定义为剖宫产术后30天内的任何浅表切口、深部切口或器官/腔隙感染。
临床怎么用
- 对于接受标准术前头孢菌素预防的肥胖女性,剖宫产术后可考虑口服头孢氨苄和甲硝唑48小时以预防SSI(作者认为可能是有理由的)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The rate of obesity among US women has been increasing, and obesity is associated with increased risk of surgical site infection (SSI) following cesarean delivery. The optimal perioperative antibiotic prophylactic regimen in this high-risk population undergoing cesarean delivery is unknown. OBJECTIVE: To determine rates of SSI among obese women who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean delivery for the prevention of SSI in obese women (prepregnancy BMI ≥30) who had received standard intravenous preoperative cephalosporin prophylaxis. Randomization was stratified by intact vs rupture of membranes prior to delivery. The study was conducted at the University of Cincinnati Medical Center, Cincinnati, Ohio, an academic and urban setting, between October 2010 and December 2015, with final follow-up through February 2016. INTERVENTIONS: Participants were randomly assigned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identical-appearing placebo (n = 201 participants) every 8 hours for a total of 48 hours following cesarean delivery. MAIN OUTCOMES AND MEASURES: The primary outcome was SSI, defined as any superficial incisional, deep incisional, or organ/space infections within 30 days after cesarean delivery. RESULTS: Among 403 randomized participants who were included (mean age, 28 [SD, 6] years; mean BMI, 39.7 [SD, 7.8]), 382 (94.6%) completed the trial. The overall rate of SSI was 10.9% (95% CI, 7.9%-14.0%). Surgical site infection was diagnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo group (difference, 9.0% [95% CI, 2.9%-15.0%]; relative risk, 0.41 [95% CI, 0.22-0.77]; P = .01). There were no serious adverse events, including allergic reaction, reported in either the antibiotic group or the placebo group. CONCLUSIONS AND RELEVANCE: Among obese women undergoing cesarean delivery who received the standard preoperative cephalosporin prophylaxis, a postoperative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate of SSI within 30 days after delivery. For prevention of SSI among obese women after cesarean delivery, prophylactic oral cephalexin and metronidazole may be warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01194115.
引用
- Valent AM, DeArmond C, Houston JM, et al. Effect of Post-Cesarean Delivery Oral Cephalexin and Metronidazole on Surgical Site Infection Among Obese Women: A Randomized Clinical Trial. JAMA. 2017. PMID: 28975304. doi:10.1001/jama.2017.10567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。